AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ALX Oncology shares surge 16.10% intraday after ASPEN-06 trial shows evorpacept efficacy in HER2+ gastric cancer with high CD47 expression.
ByAinvest
Friday, Nov 7, 2025 3:21 pm ET1min read
ALX Oncology surged 16.10% intraday after announcing robust clinical data from its ASPEN-06 trial, showing evorpacept’s 65% objective response rate in HER2+ gastric cancer patients with high CD47 expression, alongside durable benefits in progression-free and overall survival. The company highlighted its Phase 2 ASPEN-09-Breast Cancer trial, set to begin enrollment in Q4 2025, and positive preclinical results for ALX2004, an EGFR-targeted ADC entering Phase 1 trials. These updates, coupled with a reduced Q3 net loss and extended cash runway into Q1 2027, reinforced investor confidence in the pipeline’s potential. Management emphasized evorpacept’s mechanism of action and biomarker-driven strategy, with Dr. Peter Schmid noting its applicability to HER2+ breast cancer post-ENHERTU®. The stock’s intraday rally reflects optimism around near-term clinical milestones and the drug’s differentiated safety profile.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet